Posted on 12 Apr 2017 by Mia Pappijn
How to cure Pharma and Medical Device Pricing?
It's been well-documented for years now: healthcare costs keep rising, straining private and public budgets, poorer patients can’t get access to necessary care, while the better-off receive unnecessary treatment, and everyone complains about the lousy system and high prices, but nothing really changes.
‘It’s going to be a long and difficult conversation, but pharma and medical device companies need to take a longer-term perspective, have the tough conversations now so that when the inevitable change, they can influence the direction taken for the good of us all.’ states Ian Tidswell. Ian is speaking and discussing with peers at the EPP Life Sciences Executive Round Table in Zurich on April 27, 2017.
Read the full blog from Ian Tidswell here.
What do you think? What can pricers in Pharma and Medical Device companies do to influence the outcome? How can we raise quality of the debate while lowering the noise level? Do you want to participate in the discussion as well, join us in an Executive Round Table on these topics in Zurich, April 27, 2017 sponsored by the European Pricing Platform where this and other topics will be discussed.
If you also want to discuss with us, ask firstname.lastname@example.org – our LifeSciences Manager – for your personal invitation.